Get the app
US › Healthcare

Dermata Therapeutics Inc (DRMA)

US · Healthcare · Biotechnology

$1.16+0.87%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Net profit
$-3.0M
EPS
$-0.74
EPS estimate
$-0.55

EPS came in at -0.74 against a street estimate of -0.55 — a miss of 34.5%.

Key statistics

Market cap
$5.9M
Forward P/E
0.0
P/B
1.68
Book value
$0.87
EPS (TTM)
$-4.31
52-week high
$6.22
52-week low
$0.95
50-day MA
$1.31
200-day MA
$1.58
Beta
0.69

Analyst view

Analysts rate Dermata Therapeutics Inc a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $4.00.

Shareholding

Insiders
27.35%
Institutions
7.77%

Largest institutional holders

FundStake
Geode Capital Management, LLC1.82%
UBS Group AG1.34%
Welch & Forbes LLC0.75%
Advisory Alpha, LLC0.38%
Mcf Advisors, LLC0.07%
Tower Research Capital LLC0.03%
SBI Securities Co Ltd0.00%
Citigroup Inc0.00%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Dermata Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncMerck & Company IncUnitedHealth Group IncorporatedNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncNovo Nordisk A/SGilead Sciences IncAbbott Laboratories

Data updated 2026-09-18.